Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Centre Oscar Lambret
Centre Oscar Lambret
Centre Oscar Lambret
Institut Bergonié
Endeavor Biomedicines, Inc.
Washington University School of Medicine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Institut Bergonié
Lytix Biopharma AS
Bayer
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Ipsen
Chipscreen Biosciences, Ltd.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Yonsei University
National Cancer Institute (NCI)
Italian Sarcoma Group
Radboud University Medical Center
Italian Sarcoma Group
Fundació Sant Joan de Déu
Columbia University
University of Miami
ImmunityBio, Inc.
ImmunityBio, Inc.
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
UNICANCER
National Institutes of Health Clinical Center (CC)
Stanford University
Wake Forest University Health Sciences
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Canadian Cancer Trials Group
University Health Network, Toronto
Dana-Farber Cancer Institute
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
AIO-Studien-gGmbH
Yonsei University
Gradalis, Inc.
University Medicine Greifswald